Jump to content

Recommended Posts

After the recent write-up on Value Investors Club on Ardelyx, I became interested in this stock. The thesis seems simple enough (less pills, less side effects); however, I am new to Biotech investing and I am aware it is outside my circle of competence. Could anyone shed light on how likely it is for this drug to be approved by the FDA and commercialized? I am aware it has been approved by the FDA in 2019 by only for IBS. 

 

I have also read the recent write up on VIC on KPTI and am interested on anyone’s thoughts.

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...